Company intelligence / Profile preview

Zhuhai Kaizhong

Zhuhai, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Zhuhai Kaizhong is a clinical-stage biotechnology company headquartered in Zhuhai, China, specializing in the development of innovative small molecule drugs. The company primarily focuses on the ubiquitin-proteasome system (UPS) to treat various forms of cancer. Its lead candidate, KZ-001, is a highly selective USP7 inhibitor designed to restore the activity of tumor suppressors like p53, thereby inducing apoptosis in cancer cells. Zhuhai Kaizhong's research and development efforts are centered on creating targeted therapies that overcome resistance to existing treatments.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Zhuhai Kaizhong.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhuhai Kaizhong.

Explore the full profile